华东医药高端医美产品MaiLi Precise国内注册申请获受理

Core Insights - Huadong Medicine has made significant progress in the medical aesthetics sector with the acceptance of its MaiLi Precise product registration by the NMPA, marking a key milestone in the development of its high-end hyaluronic acid product line in China [1][2] Company Developments - The full subsidiary, Xinkelimeixue (Hangzhou) Medical Technology Co., Ltd., received the acceptance notice for the registration of MaiLi Precise, a Class III medical device containing lidocaine [1] - The MaiLi series includes four products: MaiLi Precise, MaiLi Define, MaiLi Volume, and MaiLi Extreme, all of which are already available in Europe [1] - MaiLi Extreme, known for its high concentration of hyaluronic acid, is set to be commercially launched in China by May 2025 [1] Product Details - MaiLi Precise is the lowest concentration product in the MaiLi series, designed to provide immediate correction for under-eye hollows, demonstrating good filling performance and safety in clinical trials [2] - The hyaluronic acid market in China is experiencing rapid growth, with a market size increase from 3.1 billion yuan in 2017 to 6.3 billion yuan in 2021, and projected to reach 44.1 billion yuan by 2030, reflecting a compound annual growth rate of 24.2% from 2021 to 2030 [2] Industry Context - The medical aesthetics hyaluronic acid market is characterized by both rapid growth and intense competition, with nearly 70 approved products in the domestic market by May 2025 [2] - The unique OxiFree "oxygen-free" cross-linking technology of the MaiLi series allows for stronger support and a lighter, more flexible effect with less product usage, positioning it as a safe and effective choice for consumers [3] Strategic Direction - Medical aesthetics is a core strategic area for Huadong Medicine, which aims to enhance its brand presence and market education domestically while promoting the registration and launch of more high-end medical aesthetic products both domestically and internationally [3]